24
Participants
Start Date
March 1, 2021
Primary Completion Date
June 1, 2023
Study Completion Date
December 1, 2023
Tislelizumab
Tislelizumab, 200mg, Q3W ,use until disease progression
Zhou Chengzhi, Guangzhou
Zhou Chengzhi
OTHER